Home/Filings/4/0000899243-22-016293
4//SEC Filing

Gross Paul Edward 4

Accession 0000899243-22-016293

CIK 0001466301other

Filed

May 2, 8:00 PM ET

Accepted

May 3, 4:15 PM ET

Size

15.1 KB

Accession

0000899243-22-016293

Insider Transaction Report

Form 4
Period: 2022-05-01
Transactions
  • Sale

    Common Stock

    2022-05-02$1.97/sh2,508$4,94079,393 total
  • Exercise/Conversion

    Common Stock

    2022-05-01+4,62584,018 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-05-015,62316,872 total
    Common Stock (5,623 underlying)
  • Exercise/Conversion

    Common Stock

    2022-05-01+5,62381,901 total
  • Sale

    Common Stock

    2022-05-02$1.97/sh2,062$4,06281,956 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-05-014,62532,375 total
    Common Stock (4,625 underlying)
Footnotes (5)
  • [F1]Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  • [F2]Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
  • [F3]This transaction was executed in multiple trades at prices ranging from $1.9515 to $1.9700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]On February 1, 2019, the reporting person was granted 89,982 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
  • [F5]On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Issuer

Clovis Oncology, Inc.

CIK 0001466301

Entity typeother

Related Parties

1
  • filerCIK 0001766329

Filing Metadata

Form type
4
Filed
May 2, 8:00 PM ET
Accepted
May 3, 4:15 PM ET
Size
15.1 KB